ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chhajed, P.N.
Right arrow Articles by Glanville, A.R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chhajed, P.N.
Right arrow Articles by Glanville, A.R.
Eur Respir J 2002; 19:469-471
Copyright ©ERS Journals Ltd 2002


Achilles tendon disease in lung transplant recipients: association with ciprofloxacin

P.N. Chhajed, M.L. Plit, P.M. Hopkins, M.A. Malouf and A.R. Glanville

Heart Lung Transplant Unit, St. Vincent's Hospital, Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia

CORRESPONDENCE: P.N. Chhajed, Heart Lung Transplant Unit, St. Vincent's Hospital, deLacy Building, Level 14, Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. Fax: 61 293324267. E-mail: chhajed@hotmail.com

Keywords: achilles tendon, ciprofloxacin, fluoroquinolane, lung transplant, tendonitis, tendon rupture

Received: June 29, 2001
Accepted September 17, 2001

Achilles tendonitis or rupture are uncommon complications following the use of fluoroquinolones, with a reported incidence in the general population of 0.4%. The aims of the current study were to determine the incidence of Achilles tendon disease (ATD) in lung transplant recipients (LTR) and to identify risk factors.

Questionnaires were sent to 150 LTR of whom 101 responded (67%). Twenty-two LTR (21.8%) experienced ATD (tendonitis 16, rupture six). The mean age of LTR who developed ATD was 52.9±6.1 yrs (range: 19–63.5 yrs).

Only the use of ciprofloxacin was significantly associated with ATD (p<0.05). Age, sex, underlying disease necessitating transplantation, serum creatinine and cyclosporine levels were not associated with ATD. The association between ciprofloxacin and ATD was not dose related. Of the 72 LTR who had received ciprofloxacin, 20 (28%) developed ATD (tendonitis 15, rupture five). In patients receiving ciprofloxacin, there was no association between the mean cumulative dose of prednisolone and ATD. Tendon rupture occurred with a lower ciprofloxacin dosage than tendonitis and the mean recovery duration was significantly longer.

To conclude, lung transplant recipients receiving ciprofloxacin are at significant risk of developing Achilles tendon disease. The association between ciprofloxacin and Achilles tendon disease appears to be idiosyncratic rather than dose-related.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
A S. Mathis, V. Chan, M. Gryszkiewicz, R. T Adamson, and G. S Friedman
Levofloxacin-Associated Achilles Tendon Rupture
Ann. Pharmacother., July 1, 2003; 37(7): 1014 - 1017.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the European Respiratory Society.